Pds Biotechnology Corp Stock Revenue
| PDSB Stock | USD 2.19 0.04 1.86% |
PDS Biotechnology Corp fundamentals help investors to digest information that contributes to PDS Biotechnology's financial success or failures. It also enables traders to predict the movement of PDS Stock. The fundamental analysis module provides a way to measure PDS Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PDS Biotechnology stock.
| Last Reported | Projected for Next Year |
PDS | Revenue |
PDS Biotechnology Corp Company Revenue Analysis
PDS Biotechnology's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of PDS
Projected quarterly revenue analysis of PDS Biotechnology Corp provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of PDS Biotechnology match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in PDS Biotechnology's stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, PDS Biotechnology Corp reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
PDS Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PDS Biotechnology's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PDS Biotechnology could also be used in its relative valuation, which is a method of valuing PDS Biotechnology by comparing valuation metrics of similar companies.PDS Biotechnology is currently under evaluation in revenue category among its peers.
PDS Biotechnology Current Valuation Drivers
We derive many important indicators used in calculating different scores of PDS Biotechnology from analyzing PDS Biotechnology's financial statements. These drivers represent accounts that assess PDS Biotechnology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PDS Biotechnology's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 12.9M | 35.8M | 207.3M | 377.5M | 339.8M | 356.7M | |
| Enterprise Value | 738.7K | 7.6M | 142.6M | 327.2M | 294.4M | 309.2M |
PDS Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, PDS Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to PDS Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
PDS Biotechnology Institutional Holders
Institutional Holdings refers to the ownership stake in PDS Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of PDS Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing PDS Biotechnology's value.| Shares | Commonwealth Equity Services Inc | 2024-06-30 | 78.9 K | Amussen, Hunsaker & Associates Incorporated | 2024-09-30 | 75 K | Xtx Topco Ltd | 2024-09-30 | 67.2 K | Bank Of America Corp | 2024-06-30 | 45 K | Sherbrooke Park Advisers Llc | 2024-09-30 | 40.2 K | Vontobel Holding Ltd. | 2024-09-30 | 40 K | Bank Of New York Mellon Corp | 2024-09-30 | 29.3 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 28.2 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 27.4 K | Vanguard Group Inc | 2024-09-30 | 1.5 M | Blackrock Inc | 2024-06-30 | 487 K |
PDS Fundamentals
| Return On Equity | -1.28 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | 56.84 M | ||||
| Shares Outstanding | 37.41 M | ||||
| Shares Owned By Insiders | 3.99 % | ||||
| Shares Owned By Institutions | 12.35 % | ||||
| Number Of Shares Shorted | 3.87 M | ||||
| Price To Earning | 24.70 X | ||||
| Price To Book | 3.72 X | ||||
| EBITDA | (40.08 M) | ||||
| Net Income | (42.94 M) | ||||
| Cash And Equivalents | 52.98 M | ||||
| Cash Per Share | 1.86 X | ||||
| Total Debt | 23.85 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 12.34 X | ||||
| Book Value Per Share | 0.79 X | ||||
| Cash Flow From Operations | (33.64 M) | ||||
| Short Ratio | 10.47 X | ||||
| Earnings Per Share | (1.17) X | ||||
| Price To Earnings To Growth | (0.05) X | ||||
| Target Price | 11.5 | ||||
| Number Of Employees | 25 | ||||
| Beta | 1.93 | ||||
| Market Capitalization | 81.93 M | ||||
| Total Asset | 59.39 M | ||||
| Retained Earnings | (144.5 M) | ||||
| Working Capital | 45.43 M | ||||
| Current Asset | 39.11 M | ||||
| Current Liabilities | 4.54 M | ||||
| Net Asset | 59.39 M |
About PDS Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PDS Biotechnology Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PDS Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PDS Biotechnology Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock:Check out PDS Biotechnology Piotroski F Score and PDS Biotechnology Altman Z Score analysis. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.40) | Return On Equity (1.28) |
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.